Paper Details

  1. Home
  2. Paper Details

Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.

Author: AdatuFrancis, ChandaDuncan M, ConnollyCathy, DoullaBasra, EgwagaSaidi, EzechiOliver, JolobaMoses, KapataNathan, KapotweVincent, KirengaBruce J, KohiWanze, LuwagaHenry, LyantumbaLucinda, MassagaJulius, MfinangaSayoki G, MthiyaneThuli, MutayobaBeatrice, MuwongeCatherine, MwabaPeter, MzyeceJudith, NyakoojoGrace, OnyebujohPhilip, PymAlex, RustomjeeRoxana, SinkalaEdford, VahediMahnaz, YimerGetnet, ZumlaAlimuddin

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Antiretroviral therapy (ART) is recommended for all HIV-positive patients with tuberculosis, but evidence for early initiation is limited. This study investigates the impact of ART initiation timing on tuberculosis treatment outcomes in patients with higher CD4 counts.
Paper Details　
Original Abstract of the Article :
WHO guidelines recommend early initiation of antiretroviral therapy (ART) irrespective of CD4 cell count for all patients with tuberculosis who also have HIV, but evidence supporting this approach is poor quality. We assessed the effect of timing of ART initiation on tuberculosis treatment outcomes ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1473-3099(14)70733-9

データ提供：米国国立医学図書館（NLM）

Timing of Antiretroviral Therapy for HIV-Positive Patients with Tuberculosis

This study delves into the complex world of HIV and tuberculosis co-infection. It's like navigating a vast desert, where two formidable challenges converge. The researchers investigated the impact of early versus delayed initiation of antiretroviral therapy (ART) on tuberculosis treatment outcomes in HIV-positive patients.

Early ART Initiation: A Promising Approach

The study provides strong evidence supporting the World Health Organization's (WHO) guidelines recommending early ART initiation for all patients with tuberculosis and HIV, regardless of CD4 cell count. It's like discovering a hidden oasis in the desert, offering a vital lifeline to those facing dual challenges.

Optimizing Treatment for Dual Infections

The findings emphasize the importance of prompt and comprehensive treatment for patients with HIV and tuberculosis co-infection. It's like ensuring a safe and successful journey across a treacherous desert. This study provides valuable insights for healthcare providers, guiding them towards optimal treatment strategies.

Dr. Camel's Conclusion

This study serves as a beacon of hope in the fight against HIV and tuberculosis co-infection. It underscores the importance of early intervention and comprehensive care to improve treatment outcomes. This research is a testament to the power of collaborative efforts to combat complex health challenges.

Date :
  1. Date Completed 2014-09-29
  2. Date Revised 2022-03-16
Further Info :

Pubmed ID

24810491

DOI: Digital Object Identifier

10.1016/S1473-3099(14)70733-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.